Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

John Imig to 8,11,14-Eicosatrienoic Acid

This is a "connection" page, showing publications John Imig has written about 8,11,14-Eicosatrienoic Acid.

 
Connection Strength
 
 
 
4.886
 
  1. Imig JD, Hye Khan MA, Burkhan A, Chen G, Adebesin AM, Falck JR. Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity. Int J Mol Sci. 2021 Mar 10; 22(6).
    View in: PubMed
    Score: 0.751
  2. Imig JD, Jankiewicz WK, Khan AH. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. Hypertension. 2020 07; 76(1):3-15.
    View in: PubMed
    Score: 0.712
  3. Neck?r J, Hsu A, Hye Khan MA, Gross GJ, Nithipatikom K, Cyprov? M, Ben?k D, Hlav?ckov? M, Sot?kov?-Ka?parov? D, Falck JR, Sedmera D, Kol?r F, Imig JD. Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1a via downregulation of prolyl hydroxylase 3. Am J Physiol Heart Circ Physiol. 2018 11 01; 315(5):H1148-H1158.
    View in: PubMed
    Score: 0.627
  4. Khan MA, Liu J, Kumar G, Skapek SX, Falck JR, Imig JD. Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J. 2013 Aug; 27(8):2946-56.
    View in: PubMed
    Score: 0.435
  5. Imig JD. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:2-7.
    View in: PubMed
    Score: 0.427
  6. Imig JD, Dimitropoulou C, Reddy DS, White RE, Falck JR. Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels. Microcirculation. 2008 Feb; 15(2):137-50.
    View in: PubMed
    Score: 0.303
  7. Dimitropoulou C, West L, Field MB, White RE, Reddy LM, Falck JR, Imig JD. Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins Other Lipid Mediat. 2007 Feb; 83(1-2):50-61.
    View in: PubMed
    Score: 0.278
  8. Campbell WB, Imig JD, Schmitz JM, Falck JR. Orally Active Epoxyeicosatrienoic Acid Analogs. J Cardiovasc Pharmacol. 2017 Oct; 70(4):211-224.
    View in: PubMed
    Score: 0.148
  9. J?chov? ?, Kopkan L, Huskov? Z, Dole?elov? ?, Neck?r J, Kujal P, Vernerov? Z, Kramer HJ, Sadowski J, Kompanowska-Jezierska E, Reddy RN, Falck JR, Imig JD, Cervenka L. Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2016 10; 34(10):2008-25.
    View in: PubMed
    Score: 0.138
  10. Sporkov? A, Reddy RN, Falck JR, Imig JD, Kopkan L, Sadowski J, Cervenka L. Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Rats' Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids. Am J Med Sci. 2016 05; 351(5):513-9.
    View in: PubMed
    Score: 0.132
  11. Al?nov? P, Huskov? Z, Kopkan L, Sporkov? A, J?chov? ?, Neck?r J, Imig JD, Klevstig M, Kol?r F, Rami Reddy N, Falck JR, Sadowski J, Nishiyama A, Kramer HJ, Melenovsk? V, Cervenkov? L, Kujal P, Vernerov? Z, Cervenka L. Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascul Pharmacol. 2015 Oct; 73:45-56.
    View in: PubMed
    Score: 0.128
  12. Imig JD. Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension. 2015 Mar; 65(3):476-82.
    View in: PubMed
    Score: 0.123
  13. Hye Khan MA, Pavlov TS, Christain SV, Neck?r J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond). 2014 Oct; 127(7):463-74.
    View in: PubMed
    Score: 0.120
  14. Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Atcha R, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. J Med Chem. 2014 Aug 28; 57(16):6965-72.
    View in: PubMed
    Score: 0.119
  15. Bukhari IA, Shah AJ, Gauthier KM, Walsh KA, Koduru SR, Imig JD, Falck JR, Campbell WB. 11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries. Am J Physiol Heart Circ Physiol. 2012 Apr 15; 302(8):H1574-83.
    View in: PubMed
    Score: 0.100
  16. Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. Am J Physiol Renal Physiol. 2011 Oct; 301(4):F765-72.
    View in: PubMed
    Score: 0.096
  17. Imig JD, Simpkins AN, Renic M, Harder DR. Cytochrome P450 eicosanoids and cerebral vascular function. Expert Rev Mol Med. 2011 Mar 01; 13:e7.
    View in: PubMed
    Score: 0.094
  18. Cert?kov? Ch?bov? V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerov? Z, Vanourkov? Z, Kopkan L, Kramer HJ, Falck JR, Imig JD, Hammock BD, Vaneckov? I, Cervenka L. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond). 2010 Feb 23; 118(10):617-32.
    View in: PubMed
    Score: 0.087
  19. Jin L, Foss CE, Zhao X, Mills TM, Wang MH, McCluskey LP, Yaddanapud GS, Falck JR, Imig JD, Webb RC. Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. FASEB J. 2006 Mar; 20(3):539-41.
    View in: PubMed
    Score: 0.066
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.